|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents
The Chinese Hospital Pharmaceutical Market Outlook to 2014
Executive summary 10
The macroeconomic environment in China 10
The Chinese healthcare system 11
Chinese hospital market analysis 12
Key players in the Chinese hospital pharmaceuti | 0 | 1 |
| Table of Contents | 0 | 1 |
| The Chinese Hospital Pharmaceutical Market Outlook to 2014 | 0 | 1 |
| Executive summary 10 | 0 | 1 |
| The macroeconomic environment in China 10 | 0 | 1 |
| The Chinese healthcare system 11 | 0 | 1 |
| Chinese hospital market analysis 12 | 0 | 1 |
| Key players in the Chinese hospital pharmaceutical market 13 | 0 | 1 |
| Chapter 1 Scope and methodology 16 | 0 | 1 |
| Scope 16 | 0 | 1 |
| Methodology 16 | 0 | 1 |
| IMS caveat 17 | 0 | 1 |
| Chapter 2 The macroeconomic environment in China 20 | 0 | 1 |
| Summary 20 | 0 | 1 |
| Introduction 21 | 0 | 1 |
| Population profile 23 | 0 | 1 |
| Disease burden 24 | 0 | 1 |
| Demographic factors in the Chinese healthcare system 27 | 0 | 1 |
| Age profile 27 | 0 | 1 |
| Modernization 28 | 0 | 1 |
| Affordability 28 | 0 | 1 |
| Economic landscape 29 | 0 | 1 |
| Healthcare spending 30 | 0 | 1 |
| Key events in China’s economic landscape 31 | 0 | 1 |
| The increased importance of domestic consumption 31 | 0 | 1 |
| China’s economic growth in 2009 could be much worse than expected 31 | 0 | 1 |
| Measures that could mitigate the economic downturn in China 32 | 0 | 1 |
| Environmental landscape 33 | 0 | 1 |
| Chapter 3 The Chinese healthcare system 36 | 0 | 1 |
| Summary 36 | 0 | 1 |
| Introduction 37 | 0 | 1 |
| Recent developments in the healthcare sector 38 | 0 | 1 |
| All villages in China to have a medical clinic in the next three years 38 | 0 | 1 |
| The Chinese government will deal with rural medical staff shortages 38 | 0 | 1 |
| Amended healthcare reforms will strengthen the healthcare system | 0 | 1 |
| in urban and rural areas 39 | 0 | 1 |
| An essential drugs list (EDL) to curb the rising drug prices in China 39 | 0 | 1 |
| The Chinese MOH takes responsibility for food safety monitoring 40 | 0 | 1 |
| Chinese drug regulatory system 40 | 0 | 1 |
| Intellectual property protection 42 | 0 | 1 |
| Pricing and reimbursement 44 | 0 | 1 |
| The Chinese drug approval system 45 | 0 | 1 |
| Drug advertising in China 47 | 0 | 1 |
| The drug distribution system 47 | 0 | 1 |
| The future of Chinese healthcare reforms 49 | 0 | 1 |
| Chinese biotech developments 50 | 0 | 1 |
| Improving scientific base 51 | 0 | 1 |
| Chinese biosimilar market 52 | 0 | 1 |
| Major biosimilars in China 54 | 0 | 1 |
| Chapter 4 Chinese hospital market analysis 58 | 0 | 1 |
| Summary 58 | 0 | 1 |
| Introduction 59 | 0 | 1 |
| The Chinese hospital pharmaceutical market 60 | 0 | 1 |
| Traditional Chinese medicines (TCMs) 61 | 0 | 1 |
| The domestic Chinese pharmaceutical market 63 | 0 | 1 |
| Multinationals versus domestic companies 64 | 0 | 1 |
| Investment in China based R&D 65 | 0 | 1 |
| Therapy area analysis 66 | 0 | 1 |
| Therapy area sales forecast 70 | 0 | 1 |
| Leading products dynamics 71 | 0 | 1 |
| Leading products sales forecast 72 | 0 | 1 |
| Chapter 5 Key players in the Chinese hospital pharmaceutical market 76 | 0 | 1 |
| Summary 76 | 0 | 1 |
| Introduction 77 | 0 | 1 |
| Competitive positioning of the top pharmaceutical players in hospital settings 78 | 0 | 1 |
| Detailed analysis of key players in the Chinese hospital pharmaceutical market 79 | 0 | 1 |
| Pfizer 79 | 0 | 1 |
| Overview 79 | 0 | 1 |
| Sales focus by leading therapeutic area 80 | 0 | 1 |
| Marketed product portfolio 82 | 0 | 1 |
| Pfizer’s pipeline focus 83 | 0 | 1 |
| Strategic growth analysis 84 | 0 | 1 |
| AstraZeneca 85 | 0 | 1 |
| Overview 85 | 0 | 1 |
| Sales focus by leading therapeutic area 86 | 0 | 1 |
| Marketed product portfolio 88 | 0 | 1 |
| AstraZeneca’s pipeline focus 90 | 0 | 1 |
| Strategic growth analysis 91 | 0 | 1 |
| Bayer 92 | 0 | 1 |
| Overview 92 | 0 | 1 |
| Sales focus by leading therapeutic area 93 | 0 | 1 |
| Marketed product portfolio 95 | 0 | 1 |
| Bayer’s pipeline focus 96 | 0 | 1 |
| Strategic growth analysis 97 | 0 | 1 |
| Sanofi-Aventis 98 | 0 | 1 |
| Overview 98 | 0 | 1 |
| Sales focus by leading therapeutic area 99 | 0 | 1 |
| Marketed product portfolio 101 | 0 | 1 |
| Sanofi-Aventis’s pipeline focus 103 | 0 | 1 |
| Strategic growth analysis 104 | 0 | 1 |
| Roche 106 | 0 | 1 |
| Overview 106 | 0 | 1 |
| Sales focus by leading therapeutic area 107 | 0 | 1 |
| Marketed product portfolio 108 | 0 | 1 |
| Roche’s pipeline focus 110 | 0 | 1 |
| Strategic growth analysis 111 | 0 | 1 |
| Novartis 112 | 0 | 1 |
| Overview 112 | 0 | 1 |
| Sales focus by leading therapeutic area 113 | 0 | 1 |
| Marketed product portfolio 115 | 0 | 1 |
| Novartis’s pipeline focus 117 | 0 | 1 |
| Strategic growth analysis 118 | 0 | 1 |
| Chapter 6 Appendix 122 | 0 | 1 |
| Anatomical Therapeutic Classification (ATC) 122 | 0 | 1 |
| A: Alimentary tract and metabolism 122 | 0 | 1 |
| B: Blood and blood-forming organs 122 | 0 | 1 |
| C: Cardiovascular system 122 | 0 | 1 |
| D: Dermatologicals 122 | 0 | 1 |
| G: Genito-urinary system and sex hormones 123 | 0 | 1 |
| H: Systemic hormonal preparations 123 | 0 | 1 |
| J: General anti-infectives systemic 123 | 0 | 1 |
| K: Hospital solutions 123 | 0 | 1 |
| L: Antineoplastic and immunomodulating agents 123 | 0 | 1 |
| M: Musculo-skeletal system 123 | 0 | 1 |
| N: Nervous system 124 | 0 | 1 |
| P: Parasitology 124 | 0 | 1 |
| R: Respiratory system 124 | 0 | 1 |
| S: Sensory organs 124 | 0 | 1 |
| T: Diagnostic agents 124 | 0 | 1 |
| V: Various 124 | 0 | 1 |
| Glossary 125 | 0 | 1 |
| Index 126 | 0 | 1 |
| List of Figures | 0 | 1 |
| Figure 2.1: Population demographics in China, 2008 23 | 0 | 1 |
| Figure 2.2: Comparison of healthcare expenditures across seven emerging pharmaceutical markets 30 | 0 | 1 |
| Figure 3.3: Drug approval process in China 46 | 0 | 1 |
| Figure 3.4: Drug distribution channels in China 48 | 0 | 1 |
| Figure 4.5: Top 10 sub-therapy area sales in the Chinese hospital pharmaceutical market, 2008 69 | 0 | 1 |
| Figure 5.6: Pfizer’s Chinese market sales by therapy area, 2008 81 | 0 | 1 |
| Figure 5.7: AstraZeneca’s Chinese market sales by therapy area, 2008 87
Figure 5.8: Bayer’s Chinese market sales by therapy area, 2008 93
Figure 5.9: Sanofi-Aventis’s Chinese market sales by therapy area, 2008 100
Figure 5.10: Roche’s Chinese marke | 0 | 1 |
